Top

Published in:

01-01-2005 | Review Article

A Computational Positron Emission Tomography Simulation Model for Imaging β-Amyloid in Mice

Authors: Melvin K. Simmons, PhD, Ravindra Manjeshwar, PhD, Eric D. Agdeppa, PhD, Robert M. Mattheyses, PhD, Thomas R. Kiehl, MS, Michael C. Montalto, PhD

Published in: Molecular Imaging and Biology | Issue 1/2005

Abstract

Purpose

We aimed to develop a computational simulation model for β-amyloid (Aβ) positron emission tomography (PET) imaging.

Procedures

Model parameters were set to reproduce levels of Aβ within the PDAPP mouse. Pharmacokinetic curves of virtual tracers were computed and a PET detector simulator was configured for a commercially available preclinical PET-imaging system.

Results

We modeled the effects of Aβ therapy and tracer affinity on the ability to differentiate Aβ levels by PET. Varying affinity had a significant effect on the ability to quantitate Aβ. Further, PET tracers for Aβ monomers were more sensitive to the therapeutic reduction in Aβ levels than total brain amyloid. Following therapy, the decrease in total brain Aβ corresponded to the slow rate of change in total amyloid load as expected.

Conclusions

We have developed a first proof-of-concept Aβ-PET simulation model that will be a useful tool in the interpretation of preclinical Aβ imaging data and tracer development.

Farkas, T, Ferris, S, Wolf, A, et al. 1982¹⁸F-2-Deoxy-2-Fluoro-D-glucose as a tracer in the positron emission tomographic study of senile dementiaAm J Psychiatry139352353

Benson, DF, Kuhl, DE, Phelps, ME, Cummings, JL, Tsai, SY 1981Positron emission computed tomography in the diagnosis of dementiaTrans Am Neurol Assoc1066871

Frouin, V, Comtat, C, Reilhac, A, Gregoire, MC 2002Correction of partial-volume effect for PET striatal imaging: Fast implementation and study of robustnessJ Nucl Med4317151726

Ibanez, V, Pietrini, P, Alexander, GE, et al. 1998Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer’s diseaseNeurology5015851593

Yang, J, Huang, SC, Mega, M, et al. 1996Investigation of partial volume correction methods for brain FDG PET studiesIEEE Trans Nucl Sci4333223327CrossRef

Waterhouse, RN 2003Determination of lipophilicity and its use as a predictor of blood–brain barrier penetration of molecular imaging agentsMol Imaging Biol5376389CrossRef

Patlak, CS, Blasberg, RG 1985Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. GeneralizationsJ Cereb Blood Flow Metab5584590PubMed

Patlak, CS, Blasberg, RG, Fenstermacher, JD 1983Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake dataJ Cereb Blood Flow Metab317PubMed

Logan, J 2000Graphical analysis of PET data applied to reversible and irreversible tracersNucl Med Biol27661670CrossRefPubMed

10.

Logan, J, Fowler, JS, Volkow, ND, et al. 1990Graphical analysis of reversible radioligand binding from time–activity measurements applied to [N-¹¹C-methyl]-(−)-cocaine PET studies in human subjectsJ Cereb Blood Flow Metab10740747

11.

Shoghi-Jadid, K, Small, GW, Agdeppa, ED, et al. 2002Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer’s diseaseAm J Geriatr Psychiatry102435CrossRefPubMed

12.

Skovronsky, DM, Zhang, B, Kung, MP, Kung, HF, Trojanowski, JQ, Lee, VM 2000In vivo detection of amyloid plaques in a mouse model of Alzheimer’s diseaseProc Natl Acad Sci U S A9776097614CrossRef

13.

Klunk, WE, Engler, H, Nordberg, A, et al. 2004Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-BAnn Neurol55306319CrossRefPubMed

14.

Okamura, N, Suemoto, T, Shimadzu, H, et al. 2004Styrylbenzoxazole derivatives for in vivo imaging of amyloid plaques in the brainJ Neurosci2425352541CrossRef

15.

Minoshima, S, Frey, KA, Cross, DJ, Kuhl, DE 2004Neurochemical imaging of dementiasSemin Nucl Med347082

16.

Beekman, FJ, Kamphuis, C, King, MA, Rijk, PP, Viergever, MA 2001Improvement of image resolution and quantitative accuracy in clinical single photon emission computed tomographyComput Med Imaging Graph25135146CrossRef

17.

Zaidi, H 1999Relevance of accurate Monte Carlo modeling in nuclear medical imagingMed Phys26574608CrossRef

18.

Zaidi, H, Scheurer, AH, Morel, C 1999An object-oriented Monte Carlo simulator for 3D cylindrical positron tomographsComput Methods Programs Biomed58133145CrossRef

19.

Peter, J, Gilland, DR, Jaszczak, RJ, Coleman, RE, Suganuma, R, Ogawa, K 1999Four-dimensional superquadric-based cardiac phantom for Monte Carlo simulation of radiological imaging systemsIEEE Trans Nucl Sci4622112227CrossRef

20.

Suganuma, R, Ogawa, K 2000Effective description of a 3D object for photon transportation in Monte Carlo simulationIEEE Trans Nucl Sci4710241029CrossRef

21.

Baxter, LT, Yuan, F, Jain, RK 1992Pharmacokinetic analysis of the perivascular distribution of bifunctional antibodies and haptens: Comparison with experimental dataCancer Res5258385844

22.

Praxmarer, M, Sung, C, Bungay, PM, Osdol, WW 2001Computational models of antibody-based tumor imaging and treatment protocolsAnn Biomed Eng29340358CrossRef

23.

Craft, DL, Wein, LM, Selkoe, DJ 2002A mathematical model of the impact of novel treatments on the Aβ burden in the Alzheimer’s brain, CSF and plasmaBull Math Biol6410111031CrossRef

24.

Bacskai, BJ, Hickey, GA, Skoch, J, et al. 2003Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-β ligand in transgenic miceProc Natl Acad Sci U S A1001246212467CrossRef

25.

Gonzalez-Lima, F, Berndt, JD, Valla, JE, Games, D, Reiman, EM 2001Reduced corpus callosum, fornix and hippocampus in PDAPP transgenic mouse model of Alzheimer’s diseaseNeuroReport1223752379CrossRef

26.

Redwine, JM, Kosofsky, B, Jacobs, RE, et al. 2003Dentate gyrus volume is reduced before onset of plaque formation in PDAPP mice: A magnetic resonance microscopy and stereologic analysisProc Natl Acad Sci U S A10013811386CrossRef

27.

Sijbers, J 1998Signal and noise estimation from magnetic resonance imagesNatuurkundeUniversiteit Antwerpen, Antwerpen

28.

Brown, RP, Delp, MD, Lindstedt, SL, Rhomberg, LR, Beliles, RP 1997Physiological parameter values for physiologically based pharmacokinetic modelsToxicol Ind Health13407484

29.

Gibaldi, M, Perrier, D 1982Pharmacokinetics2nd edn.Marcel DekkerNew York

30.

Plenevaux, A, Weissmann, D, Aerts, J, et al. 2000Tissue distribution, autoradiography, and metabolism of 4-(2′-methoxyphenyl)-1-[2′-[N-2′′-pyridinyl)-p-[¹⁸F]fluorobenzamido]ethyl]piperazine (p-[¹⁸F]MPPF), a new serotonin 5-HT(1A) antagonist for positron emission tomography: An in vivo study in ratsJ Neurochem75803811CrossRef

31.

Mathis, CA, Wang, Y, Holt, DP, Huang, GF, Debnath, ML, Klunk, WE 2003Synthesis and evaluation of ¹¹C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agentsJ Med Chem4627402754CrossRef

32.

Lewellen, TK, Harrison, RL, Vannoy, S 1998The SimSET programLjungberg, MStrand, SEKing, MA eds. Monte Carlo simulations in nuclear medicineIOP PublishingBristol7792

33.

Shao Y, Manjeshwar RM, Jansen FP, Kumar P (2003) PSM: A PET system modeling capable of generating images with clinically relevant count density. IEEE-MIC M11-191

34.

Lewitt, RM, Muehllehner, G, Karp, JS 1994Three-dimensional reconstruction for PET by multi-slice rebinning and axial image filteringPhys Med Biol39321340CrossRef

35.

DeMattos, RB, Bales, KR, Cummins, DJ, Paul, SM, Holtzman, DM 2002Brain to plasma amyloid-beta efflux: A measure of brain amyloid burden in a mouse model of Alzheimer’s diseaseScience29522642267CrossRefPubMed

36.

DeMattos, RB, Bales, KR, Cummins, DJ, Dodart, JC, Paul, SM, Holtzman, DM 2001Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer’s diseaseProc Natl Acad Sci U S A9888508855CrossRefPubMed

37.

DeMattos, RB, Bales, KR, Parsadanian, M, et al. 2002Plaque-associated disruption of CSF and plasma amyloid-β (Aβ) equilibrium in a mouse model of Alzheimer’s diseaseJ Neurochem81229236CrossRef

38.

Wyss-Coray, T, Lin, C, Yan, F, et al. 2001TGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic miceNat Med7612618CrossRef

39.

Citron, M 2002β-Secretase as a target for the treatment of Alzheimer’s diseaseJ Neurosci Res70373379CrossRef

40.

Walsh, DM, Klyubin, I, Fadeeva, JV, et al. 2002Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivoNature416535539CrossRefPubMed

41.

Walsh, DM, Klyubin, I, Fadeeva, JV, Rowan, MJ, Selkoe, DJ 2002Amyloid-β oligomers: Their production, toxicity and therapeutic inhibitionBiochem Soc Trans30552557CrossRef

42.

Kung, MP, Skovronsky, DM, Hou, C, et al. 2003Detection of amyloid plaques by radioligands for Aβ40 and Aβ42: Potential imaging agents in Alzheimer’s patientsJ Mol Neurosci201524CrossRef

43.

Agdeppa, ED, Kepe, V, Liu, J, et al. 2001Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for β-amyloid plaques in Alzheimer’s diseaseJ Neurosci21RC189

44.

Kung, HF, Lee, CW, Zhuang, ZP, Kung, MP, Hou, C, Plossl, K 2001Novel stilbenes as probes for amyloid plaquesJ Am Chem Soc1231274012741CrossRef

45.

Kuo, YM, Emmerling, MR, Vigo-Pelfrey, C, et al. 1996Water-soluble Aβ (N-40, N-42) oligomers in normal and Alzheimer disease brainsJ Biol Chem27140774081CrossRef

46.

Dodart, JC, Bales, KR, Gannon, KS, et al. 2002Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer’s disease modelNat Neurosci5452457

47.

Lambert, MP, Viola, KL, Chromy, BA, et al. 2001Vaccination with soluble Aβ oligomers generates toxicity-neutralizing antibodiesJ Neurochem79595605CrossRef

48.

Hock, C, Konietzko, U, Streffer, JR, et al. 2003Antibodies against β-amyloid slow cognitive decline in Alzheimer’s diseaseNeuron38547554CrossRef

49.

Nicoll, JA, Wilkinson, D, Holmes, C, Steart, P, Markham, H, Weller, RO 2003Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: A case reportNat Med9448452CrossRefPubMed

50.

Hock, C, Konietzko, U, Papassotiropoulos, A, et al. 2002Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer diseaseNat Med812701275CrossRefPubMed

51.

Engler, H, Blomqvist, G, Bergstrom, M, et al. 2002First human study with a benzothiazole amyloid-imaging agent in Alzheimer’s disease and control subjectsNeurobiol Aging23S429

52.

Kemp, PM, Holmes, C, Hoffmann, SM, et al. 2003Alzheimer’s disease: Differences in technetium-99 m HMPAO SPECT scan findings between early onset and late onset dementiaJ Neurol Neurosurg Psychiatry74715719CrossRef

53.

Kitano, H 2002Computational systems biologyNature420206210CrossRef

54.

Sarachan, BD, Simmons, MK, Subramanian, P, Temkin, JM 2003Combining medical informatics and bioinformatics toward tools for personalized medicineMethods Inf Med42111115

55.

Gong, Y, Chang, L, Viola, KL, et al. 2003Alzheimer’s disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory lossProc Natl Acad Sci U S A1001041710422CrossRef

56.

Kayed, R, Head, E, Thompson, JL, et al. 2003Common structure of soluble amyloid oligomers implies common mechanism of pathogenesisScience300486489CrossRefPubMed

57.

Deane, R, Yan, S, Submamaryan, RK 2003RAGE mediates amyloid-β peptide transport across the blood–brain barrier and accumulation in brainNat Med9907913CrossRef

58.

Pluta, R, Misicka, A, Barcikowska, M, Spisacka, S, Lipkowski, AW, Januszewski, S 2000Possible reverse transport of beta-amyloid peptide across the blood–brain barrierActa Neurochir Suppl767377

59.

Zlokovic, BV 1996Cerebrovascular transport of Alzheimer’s amyloid β and apolipoproteins J and E: Possible anti-amyloidogenic role of the blood–brain barrierLife Sci5914831497CrossRefPubMed

60.

Poduslo, JF, Curran, GL, Sanyal, B, Selkoe, DJ 1999Receptor-mediated transport of human amyloid β-protein 1–40 and 1–42 at the blood–brain barrierNeurobiol Dis6190199CrossRef

Title: A Computational Positron Emission Tomography Simulation Model for Imaging β-Amyloid in Mice
Authors: Melvin K. Simmons, PhD
Ravindra Manjeshwar, PhD
Eric D. Agdeppa, PhD
Robert M. Mattheyses, PhD
Thomas R. Kiehl, MS
Michael C. Montalto, PhD
Publication date: 01-01-2005
Publisher: Springer-Verlag
Published in: Molecular Imaging and Biology / Issue 1/2005
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI: https://doi.org/10.1007/s11307-005-0952-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A Computational Positron Emission Tomography Simulation Model for Imaging β-Amyloid in Mice

Abstract

Purpose

Procedures

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Procedures

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2005

Positron Emission Tomography Imaging of Small Animals in Anticancer Drug Development

Weaving Single Photon Imaging into New Drug Development

Noninvasive Imaging of Cardiac Gene Expression and Its Future Implications for Molecular Therapy

Toward the Validation of Functional Neuroimaging as a Potential Biomarker for Alzheimer’s Disease: Implications for Drug Development

What Has Intrinsic Signal Optical Imaging Taught Us About NGF-Induced Rapid Plasticity in Adult Cortex and Its Relationship to the Cholinergic System?

Positron Emission Tomography Studies on Binding of Central Nervous System Drugs and P-Glycoprotein Function in the Rodent Brain